HIV was never dormant
The claim to come out of David Ho’s research in the mid-1990s was that HIV had been badly misread. Rather than sitting largely dormant in the body for years before AIDS finally emerged, the virus was shown to replicate continuously and rapidly, with a life cycle short enough to be measured in a day or two, generating enormous numbers of new copies every day of infection. Because the enzyme HIV uses to copy its genetic material has no proofreading step, that constant replication also throws off a steady stream of mutations, some of which happen to resist whatever drug a patient is taking. The therapeutic conclusion Ho and his collaborators drew from this was blunt: a single drug would always eventually be out-mutated, but a combination of several drugs, each blocking a different step of the virus’s life cycle, would require several resistance mutations to appear together in one viral copy, which is a far less likely event.
Tracking the fall of a virus
The evidence for rapid viral turnover came from human studies in which patients were given a potent antiretroviral drug and their blood was then sampled repeatedly to track how quickly circulating virus fell, a decline whose speed let researchers work backwards to estimate how fast the virus had been replicating and being cleared before treatment started. That reasoning fed directly into clinical trials: from April 1995, Merck and the National Institute of Allergy and Infectious Diseases tested a three-drug regimen combining the protease inhibitor indinavir with two older nucleoside drugs. Ho presented data on sustained control of HIV replication in patients on combination therapy at the 1996 International AIDS Conference, and two papers published that year in the New England Journal of Medicine reported the trial results in full, giving the field its first solid clinical evidence that combining drug classes worked where single drugs had not.
What the trial data confirmed
The clinical numbers from that period have held up well. The 1996 trials reported declines of sixty to eighty percent in the rates of AIDS progression, death and hospitalisation among patients on combination therapy compared with earlier single-drug regimens, and the following year the United States recorded its first significant fall in new HIV and AIDS cases, a forty-seven percent drop. The underlying mechanism has also held: patients who take a suppressive combination regimen consistently, without gaps, generally do not develop resistance and keep the virus suppressed for the long term, exactly as the multiple-obstacle logic predicted. That same logic extended further than treatment alone. Later studies of couples where one partner was HIV-positive and on effective therapy found no transmissions at all through condomless sex once the virus was durably suppressed, confirming that keeping viral load down protects other people as well as the patient.
Suppression is not cure
Ho’s early recommendation, widely summarised as “hit hard, hit early,” called for starting maximally aggressive combination therapy as soon as possible after diagnosis, and this specific position did not survive unchanged. Once it became clear that the older drugs used in these first combinations carried serious side effects, and that resistance could still develop under imperfect treatment conditions, guidance shifted over the following years toward regimens chosen with more attention to tolerability and long-term adherence. The deeper problem the viral dynamics work exposed, rather than solved, is that suppression is not cure: HIV persists in a latent reservoir inside long-lived memory immune cells that combination therapy cannot reach, which is why treatment, once started, is not something patients can safely stop, and why gene-editing approaches aimed at removing that reservoir have so far only reached a modest fraction of infected cells in trials.
From death sentence to chronic condition
Beyond the immediate clinical result, this work changed what an HIV diagnosis meant in practice, converting what had been a near-certain progression to fatal illness into a manageable, lifelong condition for patients who can access and maintain treatment. It also gave public health authorities a second use for the same drugs: because effective therapy lowers the amount of virus in blood and genital fluids to the point where transmission essentially stops, treating people already infected became a recognised strategy for preventing new infections, an approach significant enough that a scientific journal named it a breakthrough of the year. The scale of benefit is large by most public health estimates, with hundreds of thousands of deaths avoided annually where treatment reaches patients, though cost varies enormously by country, from a few dollars a month in some generic-supplied markets to tens of thousands of dollars a year where patented versions are used.
Is it worth your time
This is worth understanding because the reasoning is genuinely elegant and still underpins the therapy anyone with HIV takes today: not a search for a single silver-bullet drug, but a calculated bet that a virus mutating quickly cannot out-mutate several obstacles at once. It rewards anyone interested in how a laboratory insight about replication rates turned directly into a treatment regimen and then into a public health strategy within a few years. It is a less complete story for anyone hoping for resolution, though, since the same research that explained why combination therapy works also explained why it cannot yet be stopped, and the reservoir problem it identified remains substantially unsolved three decades later.